Insight Molecular Diagnostics (NASDAQ:IMDX – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.
Several other analysts have also recently commented on the stock. BTIG Research restated a “neutral” rating and set a $1.00 price target on shares of Insight Molecular Diagnostics in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insight Molecular Diagnostics in a research note on Monday, September 21st. Lake Street Capital cut their target price on shares of Insight Molecular Diagnostics to $9.00 and set a “buy” rating for the company in a research report on Friday. Stephens reissued an “equal weight” rating and set a $4.00 target price on shares of Insight Molecular Diagnostics in a research note on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of Insight Molecular Diagnostics in a research note on Tuesday, August 18th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Insight Molecular Diagnostics has a consensus rating of “Hold” and a consensus price target of $5.75.
Get Our Latest Stock Analysis on Insight Molecular Diagnostics
Insight Molecular Diagnostics Trading Up 17.5%
Insight Molecular Diagnostics (NASDAQ:IMDX – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.19) EPS for the quarter. The company had revenue of $0.56 million for the quarter.
Insider Buying and Selling at Insight Molecular Diagnostics
In other news, major shareholder Broadwood Partners, L.P. purchased 3,428,571 shares of Insight Molecular Diagnostics stock in a transaction dated Tuesday, November 17th. The stock was acquired at an average cost of $1.75 per share, for a total transaction of $5,999,999.25. Following the acquisition, the insider directly owned 16,113,455 shares in the company, valued at $28,198,546.25. This represents a 27.03% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.21% of the stock is owned by company insiders.
About Insight Molecular Diagnostics
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Further Reading
- Five stocks we like better than Insight Molecular Diagnostics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Insight Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insight Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
